The nuclear receptor Liver X Receptor (LXR) is a ligand-activated transcription factor that has been implicated in control of chronic inflammation by downregulating pro-inflammatory T cell responses. An impaired function of regulatory T cells, a subset of CD4+ T cells with a crucial role in maintaining lymphocytes homeostasis and immune regulation, is frequently observed in chronic inflammatory diseases. We observed that pharmacological activation of LXR in T cells not only resulted in a thorough suppression of Th1 and Th17 polarization in vitro, but also significantly induced regulatory T cells (Treg) cell differentiation in a receptorspecific fashion. In line with this, systemic LXR activation by oral treatment of mice with the LXR agonist GW3965 induced gut-associated regulatory T cells in vivo. Importantly, such LXR-activated Tregs had a higher suppressive capacity in functional in vitro coculture assays with effector T cells. Our data thus point towards a dual role of LXR-mediated control of inflammation by suppression of pro-inflammatory T cells and reciprocal induction of regulatory T cells.
Introduction
Regulatory T cells (Treg) are a subset of CD4+ T cells that play a key role in prevention of autoimmune diseases, maintainance of immune homeostasis and modulation of immune responses during infection [1] . Forkhead box P3 (FoxP3), the master transcription factor of Treg, is crucial for development of suppressive function [2, 3] .
Interestingly in a variety of autoimmune diseases, including both organ-specific (multiple sclerosis, type 1 diabetes) and systemic (rheumatoid arthritis) diseases a loss of Treg functionality has been observed, while Treg numbers were unaffected or even increased [4] [5] [6] .
In vivo, Treg are comprised of either thymus-derived Treg (tTreg, also natural Treg (nTreg)) or differentiate from peripheral naïve CD4+ T cells (induced Treg-iTreg) [7] . Besides expressing FoxP3, Treg are characterized by constitutive CD25 expression and low / absent CD127 expression [8] [9] [10] [11] . CD25 is part of a high-affinity IL-2 receptor (IL-2R) and is essential for generation, expansion and suppressive capacity of Treg [12, 13] . FoxP3 induces high expression of CD25 as well as expression of CTLA-4, a Treg-associated surface molecule [14] . CTLA-4 is also implicated in the suppressive capacity of Treg and mediates cell contact-dependent downregulation of the costimulatory molecules CD80 and CD86 on APCs [10, 14, 15] , which results in tolerogenized dendritic cells (DCs) that further augment Treg induction [16, 17] . Induced Treg develop extrathymically from conventional CD4+ cells under inflammatory and non-inflammatory conditions [18] . Similar to nTreg, iTreg express FoxP3, CD25, and CTLA-4, and exhibit a potent suppressive capacity as their main feature [19] . Recently Helios, a member of the Ikaros transcription factor family, was identified as a potential marker to discriminate between nTreg and iTreg, as Helios is upregulated in nTreg compared to iTreg [20] . Although there is evidence, that Helios might be induced during T cell activation and proliferation in both subsets, Helios remains the best marker so far to distinguish nTreg from iTreg and allows discrimination in both humans and mice [21] [22] [23] [24] .
The liver X receptor (LXR) is a ligand-activated transcription factor that belongs to the group of nuclear receptors (NR) and exists in two isoforms: The first is LXRα, which is expressed specifically in liver, intestine, adipose tissue, lung and macrophages. The second is LXRβ, which is ubiquitously expressed [25] [26] [27] . Both isoforms are expressed by CD4+ T cells and macrophages [28, 29] . Ligand-based activation of LXRs leads to the formation of a heterodimer with retinoid X receptor (RXR), which in turn allows the regulation of genes with a central role in the modulation of cholesterol homeostasis and fatty acid metabolism [30] . Besides physiological ligands, such as oxysterols and intermediates of the biosynthetic cholesterol pathway, potent synthetic ligands are available including T0901317 and GW3965 [31] .
Pharmacological LXR activation has been shown to be efficient in preclinical models of inflammation including atherosclerosis [ [36] . LXR-deficient mice show a higher susceptibility and aggravated disease progression in the colitis model, which is linked to increased proinflammatory cytokine and chemokine expression [36] . In turn, pharmacological receptor activation ameliorated disease progression and increased survival. In a mouse model of multiple sclerosis pharmacological activation of LXR resulted in an ameliorative effect linked to decreased effector T cell responses and inhibition of IL-23 receptor and IL-17 expression [35, 37, 38] . Furthermore mice deficient for LXR were reported to develop an aggravated disease.
Taken together, these studies suggest that LXR is a strong negative regulator of proinflammatory processes [34-36] with a direct relevance in pro-inflammatory T cells. Interestingly, it is known that LXR-related receptor RXR regulates pro-inflammatory T cell differentiation while reciprocally inducing Treg differentiation when heterodimerizing with the retinoid acid receptor (RAR). Moreover, dietary changes in cholesterol uptake of chronic hepatitis C patients, known for increased levels of Th17 cells, were reported to result in increased expression of LXR and LXR-target genes while improving the Treg/Th17 balance in peripheral immune cells. This raised the question whether pharmacological LXR activation in T cells might also promote formation of functional Treg, thereby further supporting control of inflammation. Hence, we addressed the role of LXRactivation in Treg.
Results

LXR ligand GW3965 controls pro-inflammatory T cell polarization while reciprocally enhancing regulatory T cell differentiation
To assess whether T cell differentiation is modulated by LXR activation, we in vitro differentiated CD4 + T cells with polarizing cytokines in the presence of TCR activation into either regulatory T cells (Treg) or pro-inflammatory Th1 and Th17 cells. In the presence of LXR activation using the pharmacological ligand GW3965, we observed significantly enhanced (Fig 1B) , demonstrating that effects of GW3965 were indeed receptor-specific. Furthermore, we addressed the capacity of other commonly used LXR agonists, i.e. synthetic ligand T0901317 and endogenous LXR ligand 22(R)-OHC, to modulate T cell differentiation. Both ligands elicited a comparable suppressive effect on Th17 cells ( Fig  1C, left) and inductive effect on Treg (Fig 1C, right) . Moreover, GW3965-based LXR activation acted in a dose-dependent manner in enhancement of Treg differentiation (Fig 1D, left) . Interestingly, LXR-mediated Treg induction was most prominent in the presence of lower TGFβ concentrations (Fig 1D, right) suggesting that LXR might promote Treg induction especially under suboptimal Treg conditions. Taken together, LXR activation not only restricts pro-inflammatory T cell generation, i.e. Th17 and Th1, but also reciprocally enhances Treg differentiation.
LXR-activation in vivo induces gut-associated regulatory T cells with enhanced suppressive capacity
We next asked whether LXR activation induces Treg also in vivo, which could potentially help to regulation of enhanced effector T cell responses. In vivo, Treg play a key role in the maintenance of gut homeostasis as both, nTreg and iTreg subpopulations, contribute to colitis suppression [20] . We therefore aimed to assess the impact of systemic LXR activation on gutassociated Treg. To this end, we treated wildtype mice with GW3965 by daily oral gavage and analyzed the frequency of Treg after seven days of treatment in gut-associated mesenteric lymph nodes (Mes. LN) as well as gut-associated lymphoid structures, i.e. Peyer's Patches and non-draining inguinal LN (Ing. LN). We observed a significant increase in the frequency of CD4 (Fig 2B) . Furthermore, it was of interest to evaluate the potential suppressive character of LXR-induced gutassociated Treg. We therefore investigated CTLA-4 expression on Treg in mesenteric LN and Peyer's Patches (Fig 2C) upon daily oral treatment of mice with the LXR ligand GW3965. Interestingly, we observed an increase in CTLA-4 expression on Treg in mesenteric LN, whereas no alteration in CTLA-4 expression was observed on Peyer's Patches-derived Treg ( Fig 2C) . This suggests that, at least in mesenteric LN, Treg not only increase in frequency but also in their suppressive function. Taken together, also in vivo LXR activation results in induction of Treg, which is associated with an increase in CTLA-4 expression. We next wanted to assess whether LXR activation additionally modulates the suppressive capacity of Treg. Accordingly, we analyzed whether LXR-induced Treg display an increased capacity to restrict proliferation of activated CD4 + T cells and made use of a classical in vitro suppression assay setup. Here, isolated splenic Treg were treated with GW3965 for LXR activation for 24h or were left untreated, before setup of a coculture with effector T cells in the presence or absence of the agonist. We observed that LXR-activated Treg exhibited significantly enhanced suppressive properties when compared to untreated control Treg (Fig 2D) and induced a significant reduction of IFNγ and IL-17A secretion (S1C Fig), while IL-10, IL-4, GM-CSF and IL-6 secretion remain unaffected (S1D Fig.) . This demonstrates that LXR-activation not only results in an increase in Treg numbers, but more importantly functionally alters Treg, which then display enhanced suppressive capacity.
Discussion
In the current study, we investigated the influence of pharmacological LXR activation on the polarization of CD4+ T cells. We here report that LXR suppresses pro-inflammatory T cell differentiation while reciprocally promoting Treg differentiation in vitro and inducing gut-associ- . In spite of the apparent association between LXR and RXR, so far only suppressive effects on pro-inflammatory T cells have been reported for LXR. We here observed strong induction of Treg differentiation upon pharmacological LXR activation in vitro, while reciprocally Th1 and Th17 differentiation was suppressed. LXR-mediated Treg induction was most prominent under suboptimal TGFβ concentrations, which indicates that this mechanism might be especially relevant under chronic inflammatory conditions with potentially disturbed Treg formation [48, 49] .
Importantly, we could show that pharmacological LXR activation in vivo resulted in a clear induction of Treg in gut-associated lymphoid tissue, i.e. Peyer's patches and mesenteric LN, which was not observed in unrelated lymphatic tissue. Moreover, the increase in Treg frequencies was not due to recruitment of thymic-derived Treg, as the frequency of Helios positive Treg remained unchanged under GW3965-treatment [24] . These findings indicate that LXR activation via oral application of a LXR agonist might be especially relevant for control of intestinal autoimmune responses, such as in colitis. However, in light of the increasingly acknowledged role of intestinal immune responses for control of systemic autoimmunity, this effect might also be relevant in other autoimmune diseases such as Multiple sclerosis, arthritis or type 1 diabetes [50-53]. Furthermore, CTLA-4 expression was induced on Treg in mice orally treated with GW3965. This allows the hypothesis that, besides locally increased differentiation of Treg, LXR activation also enhances the suppressive capacity of gut-associated Treg. This hypothesis is supported by our finding that LXR-activation enhances the suppressive capacity of splenic Treg in vitro. After an exposition time of 96h, LXR activation was capable to boost the Treg-mediated suppression of effector T cells, thus indicating that LXR is not only involved in the generation of inducible Tregs but also enhances the suppressive capacity of existing Treg.
The possibility to differentially control Treg with anti-inflammatory properties and selfreactive conventional effector T cells by activation of NR is a potent basis to restore imbalances of immune regulation, e.g. during T cell-mediated autoimmune diseases. However, despite these promising results, NR are known to have strong metabolic properties, which limits the dosage to modulate pro-and anti-inflammatory activity. With regard to clinical use of LXR ligands, it is of interest to note, that the tolerability of pharmaceutical LXR activation is currently addressed in a clinical trial (NCT02922764) targeting LXR activation in the context of cancer treatment. These data will further reveal the potential of LXR ligands in treatment of human diseases. In addition, our findings further strengthen the therapeutic potential of LXR to ameliorate T cell-mediated chronic inflammatory diseases.
Materials and methods
Mice
Mice were maintained under specific pathogen-free conditions at the animal facility of the University of Münster (ZTE, Münster, Germany) or were purchased from either Charles River Laboratories (Sulzfeld, Germany) or from Harlan Laboratories (Horst, Netherlands). All animal experiments were performed according to the guidelines of the animal ethics committee and were approved by the governmental authorities of Nordrhein-Westfalen, Germany. LXRα/β KO mice were generated by mating LXRα KO [54] and LXRβ KO [26] mice, both acquired from The Jackson Laboratory (USA).
Nuclear receptor activation
All NR ligands were reconstituted and stored according to the supplier's instructions. Cell culture assays were carried out applying 2μM T0901317 (Tocris), 3μM GW3965 (Tocris) or 2.5μM 22(R)-OHC (Sigma-Aldrich). Mice were orally administered 20 mg/kg body weight population (CD4+, FoxP3+) from the gut-associated tissue (mes. LN, PP) was further analyzed for expression of (b) Helios and (c) CTLA-4 (n = 10). (d) Murine splenic Treg, which were incubated with DMSO or GW3965, were functionally characterized in a suppression assay. Suppression assays were performed by coculturing Treg (Treg; CD4+CD25+) with allogenic responder T cells (Tresp; CD4+CD25-) in a 2:1 ratio in the presence of anti-CD3/CD28 beads (cell to bead ratio = 30:1) and GW3965 (1.5 μM) or vehicle control (DMSO), respectively. Proliferation was assessed by flow cytometry (n = 7) and suppression was calculated and is displayed as % suppression (as described in chapter 4.6). Graphs show percentage ± SEM. *p<0.05 **p<0.01. 
Isolation of CD4+ T cells
Splenic CD4+ T cells were isolated by immunomagnetic separation using MACS microbeads (Miltenyi Biotec) according to the manufacturer's instructions.
Isolation of LN and Peyer's Patches lymphocytes
LN and individual PPs were carefully excised, washed and grinded through a metal cell strainer. PPs were incubated for 15 min in Spleen Dissociation Medium (Miltenyi Biotech) at 37˚C while shaking at 250 rpm. Both LN and PPs were subsequently grinded through a 40 μm nylon mesh cell strainer and washed twice.
Murine Th cell differentiation
Purified CD4+ cells were stimulated with 4 μg/ml plate-bound anti-CD3 (eBioscience, Clone: 145-2C11) and 1 μg/ml soluble anti-CD28 (BD, Clone: 37.51;). For Th17 differentiation, cells were cultured in the presence of 5 ng/ml recombinant human TGFβ (R&D Systems), 20 ng/ml murine IL-6 (eBioscience), 10 μg/ml anti-IFNγ (eBioscience, Clone: XMG1.2), and 10 μg/ml anti-IL-4 (eBioscience, Clone 11B11). For Th1 differentiation, cells were cultured for up to 7 d with 10 ng/ml IL-12 (PeproTech) and 10 μg/ml anti-IL-4. For Treg induction purified mouse CD4+ T cells were stimulated with 1 ng/ml rhTGF-β for 72 h if not indicated differently. Cells were restimulated and intracellularly stained for flow cytometric analysis.
Suppression assays
Suppression assays were performed as previously described 
Flow cytometry and antibodies
For intracellular staining, T cells were restimulated with 5 ng/ml PMA (Cayman Chemical) and 200 ng/ml ionomycin (Cayman Chemical) for 4 h in the presence of GolgiPlug (BD Pharmingen). Subsequently, surface staining was performed at 4˚C for 30 min. Cells were fixed and permeabilized using Cytofix/Cytoperm plus Fixation/Permeabilization Kit (BD Pharmingen). For analysis of intranuclear markers, cells were fixed and stained using the FoxP3 intranuclear staining kit (eBioscience), again incubating cells at 4˚C for 30 min both during fixation and intranuclear staining. Antibodies are summarized in Table 1 . Analysis was performed using a Gallios Flow Cytometer (Beckman Coulter) and results were analyzed with FlowJo software (Tree Star).
Cytokine detection
Cytokines in cell culture supernatants were detected using Enzyme-linked Immunosorbent Assay (ELISA) Ready-SET-Go!1 (eBioscience) and Luminex1 Screening Assay (R&D systems) according to the manufacturer's instructions. Analysis of Luminex1 assay was performed on a Bio-Plex1 MAGPIX™ Multiplex Reader (Bio-Rad) according to the manufacturer's instructions.
Statistical analysis
All results are presented as the mean±SEM. We performed statistical analyses using Student's t-test for normally distributed data or Mann-Whitney test for non-normally distributed data sets. P < 0.05 ( Ã ) was considered statistically significant; p < 0.01 ( ÃÃ ) and p < 0.001 ( ÃÃÃ ) highly significant.
Conclusions
We could demonstrate that LXR activation reduces effector T cell responses (Th1 and Th17) while concomitantly enhancing Treg differentiation. Importantly, LXR activation not only resulted in increased numbers of Treg but also promoted their capacity to suppress effector T cell proliferation. These data allow to speculate on the potential of therapeutically targeting LXR in T cells and Treg, respectively, to ameliorate T cell-mediated chronic inflammatory diseases. 
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